Immix Biopharma Newsroom

Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients

GlobeNewswireNov 25 22:32

Immix Biopharma | 10-Q: Q3 2024 Earnings Report

SECNov 13 05:42 · Announcements

H.C. Wainwright Maintains Immix Biopharma(IMMX.US) With Buy Rating, Maintains Target Price $7

Futu NewsOct 3 18:31 · Ratings

Immix Biopharma's Promising Therapeutic Candidate NXC-201 Fuels Buy Rating Amidst Strong Clinical and Financial Outlook

TipRanksOct 3 18:16 · Ratings

Express News | Immix Biopharma Inc: Now Dosing at Dose Expansion Level of 450 Mln Nxc-201 Car+T Cells

BreakingsOct 2 21:33

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

GlobeNewswireOct 2 21:32

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

GlobeNewswireSep 19 21:31

Express News | Immix Biopharma Announces DR. Raymond Comenzo, Internationally Recognized Al Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board

BreakingsSep 19 21:31

Immix Biopharma Independent Director Acquires 2.6% More Stock

Yahoo FinanceAug 29 20:49

Jason Hsu Bought 2.6% More Shares In Immix Biopharma

Simply Wall StAug 29 18:04

Sector Update: Health Care Stocks Ease in Afternoon Trading

MT NewswiresAug 29 02:11

Immix Biopharma Expands US Nexicart-2 Trial for AL Amyloidosis With 3 Clinical Sites

MT NewswiresAug 28 22:30

Immix Biopharma Expands U.S. Clinical Sites for Relapsed/refractory AL Amyloidosis Trial NEXICART-2

GlobeNewswireAug 28 21:32

Express News | Immix Biopharma Expands U.S. Clinical Sites for Relapsed/Refractory Al Amyloidosis Trial Nexicart-2

BreakingsAug 28 21:32

What Makes Immix Biopharma (IMMX) a New Buy Stock

Yahoo FinanceAug 20 00:00

Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)

TipRanksAug 19 18:40 · Ratings

Immix Biopharma | 10-Q: Q2 2024 Earnings Report

SECAug 13 05:21 · Announcements

Express News | California Institute for Regenerative Medicine Awards Funding for CAR-T Nxc-201 U.S. Al Amyloidosis Clinical Trial (Nexicart-2)

BreakingsJul 26 09:31

Immix Biopharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow JonesJul 9 18:55

HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $7 Price Target

BenzingaJul 9 18:45